Ad
related to: lisdexamfetamine and serotonin reuptake
Search results
Results From The WOW.Com Content Network
Some clinical trials that used lisdexamfetamine as an add-on therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression indicated that this is no more effective than the use of an SSRI or SNRI alone. [152]
In addition, the augmentation of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor with lisdexamfetamine, a norepinephrine–dopamine releasing agent, recently failed to separate from placebo in phase III clinical trials of individuals with treatment-resistant depression, and clinical development was ...
A number of tryptamine derivatives, specifically α-alkyltryptamines, have been found to act as SDRAs. [3] One such agent is 5-chloro-αMT (PAL-542), which has been reported as having about 64-fold selectivity for dopamine release over norepinephrine release and about 3-fold selectivity for serotonin release over dopamine release, making it a highly selective and well-balanced SDRA. [9]
Monoamine reuptake inhibitor & releasing agent: Approved: Highly efficacious, [124] [125] therapeutic effects are usually seen within 1–1.5 hours of oral administration. Lisdexamfetamine: Vyvanse, Elvanse [126] Children ≥6 years & adults Children ≥6 years & adults Children ≥6 years & adults Monoamine reuptake inhibitor & releasing agent ...
Amphetamine [note 2] (contracted from alpha-methylphenethylamine) is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity; it is also used to treat binge eating disorder in the form of its inactive prodrug lisdexamfetamine.
Toggle Serotonin antagonist and reuptake inhibitors (SARIs) subsection. ... Vyvanse) – actually norepinephrine–dopamine releasing agents (NDRAs) [7] [5]
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. . Specific indications include major depressive disorder, treatment-resistant depression, dysthymia, bipolar depression, and postpartum depression, among oth
Lisdexamfetamine, [6] Selective serotonin reuptake inhibitor [7] Binge eating disorder ( BED ) is an eating disorder characterized by frequent and recurrent binge eating episodes with associated negative psychological and social problems, but without the compensatory behaviors common to bulimia nervosa , OSFED , or the binge-purge subtype of ...